Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review

@article{Costa2018TargetingTP,
  title={Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review},
  author={R. Costa and H. Han and W. Gradishar},
  journal={Breast Cancer Research and Treatment},
  year={2018},
  volume={169},
  pages={397-406}
}
PurposeTriple-negative breast cancer (TNBC) accounts for approximately 20% of breast cancer cases. [...] Key Result In addition, new compounds with distinct specificity and potency targeting different PI3K/AKT/mTOR components and cognate molecules (e.g., mitogen-activated protein kinase) are being developed. These agents present a wide range of toxicity profiles and early efficacy signals, which must be considered prior to the advancement of new agents in later-phase clinical trials.ConclusionsThe development…Expand
Rictor promotes tumor progression of rapamycin-insensitive triple-negative breast cancer cells.
Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 77 REFERENCES
Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.
  • P. LoRusso
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas.
PD-L1 Expression in Triple-Negative Breast Cancer
...
1
2
3
4
5
...